Clinical trial

A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer.

NCT07795177

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-10-01

PhasePHASE2

Study timeline

Study start (estimated)2026-10-01Date precision: day

Registry last updated2026-08-31

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Hormone-Sensitive Prostate Cancerunresolved

Interventions

ADT plus abiraterone or other ARPIs（apalutamide, enzalutamide, rezvilutamide, darolutamide)DRUG

Sponsors & collaborators

Anhui Medical Universitylead sponsor

Mapped research locations

HefeiAnhui, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07795177 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.